This article was originally published in The Tan Sheet
Researchers at the University of California-San Francisco announce they are seeking women aged 18 to 24 to participate in the first U.S. safety study of a vaginal microbicide to prevent herpes and HIV infection. VivaGel (3% w/w SPL7013) is designed to prevent herpes and HIV infection through the use of a dendrimer molecule. Herpes and HIV molecules are "caught" in the dendrimer branches and prevented from entering and infecting human cells, lead researcher Anna-Barbara Moscicki, MD, says Nov. 29. In related news, the Canadian government announces Dec. 1 a $13.2 mil. donation to the International Partnership for Microbicides to support product development and clinical trials of microbicides for women in developing countries. In August, the Global HIV Prevention Working Group issued a report encouraging increased manufacturing of microbicides to meet public need (1"The Tan Sheet" Aug. 21, 2006, p.7)...
You may also be interested in...
Development of sufficient manufacturing capacities for microbicides will likely need to begin years in advance of regulatory approval in order to meet public health needs, an HIV prevention working group says
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.